Hirmand Mohammad 4
4 · Turning Point Therapeutics, Inc. · Filed Feb 11, 2022
Insider Transaction Report
Form 4
Hirmand Mohammad
EVP and Chief Medical Officer
Transactions
- Sale
Common Stock
2022-02-09$36.30/sh−669$24,285→ 6,838 total - Award
Common Stock
2022-02-09+18,983→ 25,821 total - Award
Common Stock
2022-02-09+15,000→ 40,821 total - Award
Stock Option (right to buy)
2022-02-09+68,367→ 68,367 totalExercise: $37.68Exp: 2032-02-08→ Common Stock (68,367 underlying)
Footnotes (4)
- [F1]Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
- [F2]The Reporting Person acquired 301 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 439 shares on December 10, 2021 pursuant to the ESPP.
- [F3]Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
- [F4]1/48th of the shares vest monthly following February 9, 2022.